esoc 2022 highlights: tenecteplase non-inferiority and cancer risk in young stroke
Published 2 years ago • 143 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
1:04
key updates from esoc 2022
-
1:32
top data from esoc 2022: attention, act, and taste-a
-
4:06
an overview of esoc 2022: major topics and important clinical trials
-
1:45
new data supports use of tenecteplase versus alteplase
-
2:47
alteplase vs tenecteplase in mevo strokes: results from act
-
3:58
should tenecteplase be routinely used for thrombolysis in acute ischemic stroke?
-
1:10
esoc 2024 highlights: tenecteplase trials and decompressive hemicraniectomy for deep ich
-
1:53
tenecteplase increasingly implemented as standard of care in acute ischemic stroke
-
1:09
global adoption of tenecteplase for acute ischemic stroke
-
39:30
ischemic stroke thrombolysis a place for tenecteplase
-
23:41
nvjc ep. 35 stroke: tenecteplase and alteplase in patients with tandem lesion stroke
-
16:41
eso-esmint expedited recommendation on ivt before mechanical thrombectomy in patients with stroke
-
18:22
the next frontiers for tenecteplase in stroke
-
6:25
tenecteplase versus alteplase: impact of time to thrombolysis on clinical outcomes
-
2:05
trace ii results: tenecteplase versus alteplase for ivt
-
1:37
advances in acute ischemic stroke at esoc 2021
-
7:47
ischaemic stroke intervention - why the acute stroke network is important
-
41:02
mini pons episode one